How to stay heart healthy in 2011: Considerations for the primary prevention of cardiovascular disease in women

Women's Health

Volumn 7, Issue 4, 2011, Pages 433-451

  Davis, Melinda B ^a,b   Duvernoy, Claire S ^a,b  

^a VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

cardiovascular risk factors; coronary heart disease; gender differences; postmenopausal hormone therapy; primary cardiovascular prevention; women

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; C REACTIVE PROTEIN; ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN; MEDROXYPROGESTERONE; MEVINOLIN; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; VITAMIN D;

AWARENESS; BRAIN HEMORRHAGE; BREAST FEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DEPRESSION; DIETARY INTAKE; DISEASE CLASSIFICATION; ESTROGEN THERAPY; EXERCISE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERLIPIDEMIA; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MATERNAL HYPERTENSION; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PREVALENCE; PRIMARY PREVENTION; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING CESSATION; STRESS; TREATMENT PLANNING; VITAMIN SUPPLEMENTATION; WOMEN'S HEALTH;

CARDIOVASCULAR DISEASES; FEMALE; HEALTH EDUCATION; HEALTH STATUS; HUMANS; LIFE STYLE; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RISK FACTORS; SOCIETIES, MEDICAL; UNITED STATES; WOMEN'S HEALTH SERVICES;

EID: 79960957854     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.11.34     Document Type: Review

References (129)

1. Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics - 2011 update: a report from the Amercian Heart Association. Circulation 123(4), e18-e209 (2011).
2. Thom T, Haase N, Rosamond W et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 113(6), e85-e151 (2006).
3. Lloyd-Jones D, Adams RJ, Brown TM et al. Heart disease and stroke statistics - 2010 update: a report from the Amercian Heart Association. Circulation 121(7), e46-e215 (2010).
4. American Heart Association: Heart disease and stroke statistics - 2009 update. Circulation 119, e21-e181 (2009).
5. Fuster V, Voute J. MDGs: chronic diseases are not on the agenda. Lancet 366(9496), 1512-1514 (2005). (Pubitemid 41540101)
6. Strong K, Mathers C, Leeder S, Beaglehole R. Preventing chronic diseases: how many lives can we save? Lancet 366(9496), 1578-1582 (2005). (Pubitemid 41540116)
7. Gersh BJ, Sliwa K, Mayosi BM, Yusuf S. Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications. Eur. Heart J. 31(6), 642-648 (2010).
8. Finkelstein EA, Khavjou OA, Mobley LR, Haney DM, Will JC. Racial/ethnic disparities in coronary heart disease risk factors among WISEWOMAN enrollees. J. Womens Health (Larchmt) 13(5), 503-518 (2004).
9. Jolly S, Vittinghoff E, Chattopadhyay A, Bibbins-Domingo K. Higher cardiovascular disease prevalence and mortality among younger blacks compared with whites. Am. J. Med. 123(9), 811-818 (2010).
10. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 28(11), 2745-2749 (2005). (Pubitemid 43951170)
11. Kragelund C, Kober L, Faber J, Steffensen R, Hildebrandt P. Metabolic syndrome and mortality in stable coronary heart disease: relation to gender. Int. J. Cardiol. 121(1), 62-67 (2007). (Pubitemid 47285381)
12. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143-3421 (2002).
13. Floren CH, Kushwaha RS, Hazzard WR, Albers JJ. Estrogen-induced increase in uptake of cholesterol-rich very low density lipoproteins in perfused rabbit liver. Metabolism 30(4), 367-375 (1981). (Pubitemid 11101150)
14. Hunt KJ, Schuller KL. The increasing prevalence of diabetes in pregnancy. Obstet. Gynecol. Clin. North Am. 34(2), 173-199 (2007). (Pubitemid 46891746)
15. Russell MA, Phipps MG, Olson CL, Welch HG, Carpenter MW. Rates of postpartum glucose testing after gestational diabetes mellitus. Obstet. Gynecol. 108(6), 1456-1462 (2006). (Pubitemid 44901021)
16. England LJ, Dietz PM, Njoroge T et al. Preventing Type 2 diabetes: public health implications for women with a history of gestational diabetes mellitus. Am. J. Obstet. Gynecol. 4(365), e361-e368 (2009).
17. Lee AJ, Hiscock RJ, Wein P, Walker SP, Permezel M. Gestational diabetes mellitus: clinical predictors and long-term risk of developing Type 2 diabetes: a retrospective cohort study using survival analysis. Diabetes Care 30(4), 878-883 (2007). (Pubitemid 46556581)
18. Feig DS, Zinman B, Wang X, Hux JE. Risk of development of diabetes mellitus after diagnosis of gestational diabetes. CMAJ 179(3), 229-234 (2008).
19. Lee H, Jang HC, Park HK, Cho NH. Early manifestation of cardiovascular disease risk factors in offspring of mothers with previous history of gestational diabetes mellitus. Diabetes Res. Clin. Pract. 78(2), 238-245 (2007). (Pubitemid 47451534)
20. Shah BR, Retnakaran R, Booth GL. Increased risk of cardiovascular disease in young women following gestational diabetes mellitus. Diabetes Care 31(8), 1668-1669 (2008).
21. Carr DB, Utzschneider KM, Hull RL et al. Gestational diabetes mellitus increases the risk of cardiovascular disease in women with a family history of Type 2 diabetes. Diabetes Care 29(9), 2078-2083 (2006). (Pubitemid 44871190)
22. Kim C, Tabaei BP, Burke R et al. Missed opportunities for Type 2 diabetes mellitus screening among women with a history of gestational diabetes mellitus. Am. J. Public Health 96(9), 1643-1648 (2006). (Pubitemid 44300929)
23. Wilson BJ, Watson MS, Prescott GJ et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ 326(7394), 845 (2003).
24. Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet 357(9273), 2002-2006 (2001). (Pubitemid 32592386)
25. Magnussen EB, Vatten LJ, Smith GD, Romundstad PR: Hypertensive disorders in pregnancy and subsequently measured cardiovascular risk factors. Obstet. Gynecol. 114(5), 961-970 (2009).
26. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ 323(7323), 1213-1217 (2001).
27. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 366(9499), 1797-1803 (2005). (Pubitemid 41642644)
28. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 335(7627), 974 (2007).
29. Romundstad PR, Magnussen EB, Smith GD, Vatten LJ. Hypertension in pregnancy and later cardiovascular risk: common antecedents? Circulation 122(6), 579-584 (2010).
30. Geelhoed JJ, Fraser A, Tilling K et al. Preeclampsia and gestational hypertension are associated with childhood blood pressure independently of family adiposity measures: the Avon longitudinal study of parents and children. Circulation 122(12), 1192-1199 (2010).
31. Melzer K, Schutz Y, Boulvain M, Kayser B. Physical activity and pregnancy: cardiovascular adaptations, recommendations and pregnancy outcomes. Sports Med. 40(6), 493-507 (2010).
32. Reaven GM: Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu. Rev. Med. 44, 121-131 (1993). (Pubitemid 23117853)
33. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for Type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab. 84(1), 165-169 (1999). (Pubitemid 29036695)
34. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38(9), 1165-1174 (1989). (Pubitemid 19250404)
35. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am. J. Med. 111(8), 607-613 (2001). (Pubitemid 34088070)
36. Talbott E, Guzick D, Clerici A et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler. Thromb. Vasc. Biol. 15(7), 821-826 (1995).
37. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 86(6), 2453-2455 (2001). (Pubitemid 32545690)
38. Schachter M, Raziel A, Friedler S, Strassburger D, Bern O, Ron-El R. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum. Reprod. 18(4), 721-727 (2003). (Pubitemid 36426948)
39. Orio F Jr, Palomba S, Spinelli L et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J. Clin. Endocrinol. Metab. 89(8), 3696-3701 (2004). (Pubitemid 39071458)
40. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF 2nd, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 88(6), 2562-2568 (2003). (Pubitemid 36724424)
41. Talbott EO, Guzick DS, Sutton-Tyrrell K et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler. Thromb. Vasc. Biol. 20(11), 2414-2421 (2000).
42. Wild RA, Carmina E, Diamanti- Kandarakis E et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the androgen excess and polycystic ovary syndrome (AE-PCOS) society. J. Clin. Endocrinol. Metab. 95(5), 2038-2049 (2010).
43. Mosca L, Benjamin EJ, Berra K et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women - 2011 update: a guideline from the Amercian Heart Association. Circulation 123(11), 1243-1262 (2011).
44. Mosca L, Banka CL, Benjamin EJ et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 115(11), 1481-1501 (2007). (Pubitemid 46648385)
45. Cooper-Dehoff RM, Egelund EF, Pepine CJ. Blood pressure lowering in patients with diabetes-one level might not fit all. Nat. Rev. Cardiol. 8(1), 42-49 (2010).
46. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III).JAMA 285(19), 2486-2497 (2001).
47. Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of Type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch. Intern. Med. 164(13), 1422-1426 (2004). (Pubitemid 38937853)
48. Norhammar A, Tenerz A, Nilsson G et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359(9324), 2140-2144 (2002). (Pubitemid 34694020)
49. Singer DE, Nathan DM, Anderson KM, Wilson PW, Evans JC. Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham heart study. Diabetes 41(2), 202-208 (1992).
50. Zavaroni I, Bonora E, Pagliara M et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N. Engl. J. Med. 320(11), 702-706 (1989). (Pubitemid 19072489)
51. Selvin E, Steffes MW, Zhu H et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N. Engl. J. Med. 362(9), 800-811 (2010).
52. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med. 358(24), 2545-2559 (2008). (Pubitemid 351831356)
53. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet 353(9147), 89-92 (1999). (Pubitemid 29088076)
54. Lloyd-Jones DM, Leip EP, Larson MG et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 113(6), 791-798 (2006).
55. D'Agostino RB, Sr, Vasan RS, Pencina MJ et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation 117(6), 743-753 (2008). (Pubitemid 351640675)
56. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA 297(6), 611-619 (2007).
57. Sibley C, Blumenthal RS, Merz CN, Mosca L. Limitations of current cardiovascular disease risk assessment strategies in women. J. Womens Health (Larchmt) 15(1), 54-56 (2006). (Pubitemid 43192863)
58. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann. Intern. Med. 145(1), 21-29 (2006). (Pubitemid 46780601)
59. Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. J. Am. Coll. Cardiol. 54(14), 1209-1227 (2009).
60. Ford ES, Ajani UA, Croft JB et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N. Engl. J. Med. 356(23), 2388-2398 (2007). (Pubitemid 46883773)
61. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N. Engl. J. Med. 343(1), 16-22 (2000). (Pubitemid 30447987)
62. McGill HC Jr, McMahan CA, Herderick EE et al. Effects of coronary heart disease risk factors on atherosclerosis of selected regions of the aorta and right coronary artery. PDAY Research group. Pathobiological determinants of atherosclerosis in youth. Arterioscler. Thromb. Vasc. Biol. 20(3), 836-845 (2000). (Pubitemid 30151701)
63. McMahan CA, Gidding SS, Malcom GT, Tracy RE, Strong JP, McHill HC Jr. Pathobiological determinants of atherosclerosis in youth risk scores are associated with early and advanced atherosclerosis. Pediatrics 118(4), 1447-1455 (2006). (Pubitemid 46393790)
64. Schuler G, Hambrecht R, Schlierf G et al. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. Circulation 86(1), 1-11 (1992).
65. Niebauer J, Hambrecht R, Velich T et al. Attenuated progression of coronary artery disease after 6 years of multifactorial risk intervention: role of physical exercise. Circulation 96(8), 2534-2541 (1997). (Pubitemid 27451342)
66. Manson JE, Greenland P, Lacroix AZ et al. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N. Engl. J. Med. 347(10), 716-725 (2002). (Pubitemid 35203902)
67. Mente A, De Koning L, Shannon HS, Anand SS. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch. Intern. Med. 169(7), 659-669 (2009).
68. Rosengren A, Hawken S, Ounpuu S et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 364(9438), 953-962 (2004). (Pubitemid 39208456)
69. Khawaja IS, Westermeyer JJ, Gajwani P, Feinstein RE. Depression and coronary artery disease: the association, mechanisms, and therapeutic implications. Psychiatry (Edgmont) 6(1), 38-51 (2009).
70. Rutledge T, Vaccarino V, Johnson BD et al. Depression and cardiovascular healthcare costs among women with suspected myocardial ischemia: prospective results from the WISE (women's ischemia syndrome evaluation) study. J. Am. Coll. Cardiol. 53(2), 176-183 (2009).
71. Lichtman JH, Bigger JT Jr, Blumenthal JA et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a Scienceadvisory from the Amercian Heart Association prevention committee of the council on cardiovascular nursing, council on clinical cardiology, council on epidemiology and prevention, and interdisciplinary council on quality of care and outcomes research: endorsed by the American psychiatric association. Circulation 118(17), 1768-1775 (2008).
72. Schwarz EB, Mcclure CK, Tepper PG et al. Lactation and maternal measures of subclinical cardiovascular disease. Obstet. Gynecol. 115(1), 41-48 (2010).
73. Schwarz EB, Brown JS, Creasman JM et al. Lactation and maternal risk of Type 2 diabetes: a population-based study. Am. J. Med. 123(9), 863 e1-e6 (2010).
74. Mora S, Glynn RJ, Hsia J, Macfadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 121(9), 1069-1077 (2010).
75. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359(21), 2195-2207 (2008).
76. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. Air Force/Texas coronary atherosclerosis prevention study. JAMA 279(20), 1615-1622 (1998). (Pubitemid 28248586)
77. Mizuno K, Nakaya N, Ohashi Y et al. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study).Circulation 117(4), 494-502 (2008).
78. Duvernoy CS, Blumenthal R. The numbers are in: statins for the primary prevention of cardiovascular disease in women. Circulation 121(9), 1063-1065 (2010).
79. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329), 71-86 (2002).
80. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 295(3), 306-313 (2006).
81. Ridker PM, Cook NR, Lee IM et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med. 352(13), 1293-1304 (2005).
82. Chiang N, Hurwitz S, Ridker PM, Serhan CN. Aspirin has a gender-dependent impact on antiinflammatory 15-epi-lipoxin A4 formation: a randomized human trial. Arterioscler. Thromb. Vasc. Biol. 26(2), e14-e17 (2006). (Pubitemid 43732186)
83. Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373(9678), 1849-1860 (2009).
84. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, Stroke Association. JBS 2. Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 91(Suppl. 5), v1-v52 (2005).
85. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev. Med. 20(1), 47-63 (1991).
86. Bairey Merz CN, Johnson BD, Sharaf BL et al. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. J. Am. Coll. Cardiol. 41(3), 413-419 (2003). (Pubitemid 36164495)
87. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ Progestin Replacement Study (HERS) research group. JAMA 280(7), 605-613 (1998). (Pubitemid 28502636)
88. Manson JE, Hsia J, Johnson KC et al. Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med. 349(6), 523-534 (2003). (Pubitemid 36951364)
89. Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial. JAMA 291(14), 1701-1712 (2004). (Pubitemid 38489892)
90. Vickers MR, Maclennan AH, Lawton B et al. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of HRT in postmenopausal women. BMJ 335(7613), 239 (2007).
91. Prentice RL, Langer RD, Stefanick ML et al. Combined analysis of women's health initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am. J. Epidemiol. 163(7), 589-599 (2006).
92. Magliano DJ, Rogers SL, Abramson MJ, Tonkin AM: Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. BJOG 113(1), 5-14 (2006).
93. Rossouw JE, Prentice RL, Manson JE et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297(13), 1465-1477 (2007). (Pubitemid 46556472)
94. Duvernoy C: Estrogen and C-reactive protein: does an alternate route lead to a more attractive destination? Thromb. Haemost. 90(1), 1-2 (2003). (Pubitemid 36873851)
95. Lacut K, Oger E, Le Gal G et al. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb. Haemost. 90(1), 124-131 (2003). (Pubitemid 36873868)
96. Oger E, Alhenc-Gelas M, Lacut K et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler. Thromb. Vasc. Biol. 23(9), 1671-1676 (2003). (Pubitemid 37108215)
97. Brosnan JF, Sheppard BL, Norris LA. Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration? Thromb. Haemost. 97(4), 558-565 (2007). (Pubitemid 46592933)
98. Ichikawa J, Sumino H, Ichikawa S, Ozaki M. Different effects of transdermal and oral HRT on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women. Am. J. Hypertens. 19(7), 744-749 (2006). (Pubitemid 43928514)
99. Sumino H, Ichikawa S, Kasama S et al. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. Atherosclerosis 189(2), 436-442 (2006). (Pubitemid 44634490)
100. Canonico M, Oger E, Plu-Bureau G et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115(7), 840-845 (2007). (Pubitemid 46294724)
101. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J. Gen. Intern. Med. 21(4), 363-366 (2006).
102. Hsia J, Langer RD, Manson JE et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch. Intern. Med. 166(3), 357-365 (2006). (Pubitemid 43244325)
103. Manson JE, Bassuk SS. Invited commentary: hormone therapy and risk of coronary heart disease why renew the focus on the early years of menopause? Am. J. Epidemiol. 166(5), 511-517 (2007). (Pubitemid 47283647)
104. Harman SM, Brinton EA, Cedars M et al. KEEPS: the kronos early estrogen prevention study. Climacteric 8(1), 3-12 (2005). (Pubitemid 40675116)
105. Duvernoy CS, Yeo AA, Wong M, Cox DA, Kim HM. Antiplatelet therapy use and the risk of venous thromboembolic events in the Raloxifene Use for The Heart (RUTH) trial. J. Womens Health (Larchmt) 19(8), 1459-1465 (2010).
106. Hooper L, Thompson RL, Harrison RA et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ 332(7544), 752-760 (2006).
107. Whelton SP, He J, Whelton PK, Muntner P. Meta-analysis of observational studies on fish intake and coronary heart disease. Am. J. Cardiol. 93(9), 1119-1123 (2004). (Pubitemid 38521040)
108. Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J. Hypertens. 20(8), 1493-1499 (2002). (Pubitemid 34921171)
109. Wang C, Harris WS, Chung M et al. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary-and secondary-prevention studies: a systematic review. Am. J. Clin. Nutr. 84(1), 5-17 (2006). (Pubitemid 44699166)
110. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 296(15), 1885-1899 (2006). (Pubitemid 44596197)
111. Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis 205(1), 255-260 (2009).
112. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J. Am. Coll. Cardiol. 41(1), 105-112 (2003). (Pubitemid 36044411)
113. Holick MF: Vitamin D deficiency. N. Engl. J. Med. 357(3), 266-281 (2007).
114. Pittas AG, Chung M, Trikalinos T et al. Systematic review: vitamin D and cardiometabolic outcomes. Ann. Intern. Med. 152(5), 307-314 (2010).
115. Wang L, Manson JE, Song Y, Sesso HD: Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Ann. Intern. Med. 152(5), 315-323 (2010).
116. Ross AC, Manson JE, Abrams SA et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine: what clinicians need to know. J. Clin. Endocrinol. Metab. 96(1), 53-58 (2011).
117. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 361(9374), 2017-2023 (2003). (Pubitemid 36695043)
118. Sesso HD, Buring JE, Christen WG et al. Vitamins E and C in the prevention of cardiovascular disease in men: the physicians' health study II randomized controlled trial. JAMA 300(18), 2123-2133 (2008).
119. Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH. Β-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J. Natl Cancer Inst. 91(24), 2102-2106 (1999). (Pubitemid 30019571)
120. Eidelman RS, Hollar D, Hebert PR, Lamas GA, Hennekens CH. Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease. Arch. Intern. Med. 164(14), 1552-1556 (2004). (Pubitemid 38970477)
121. Lonn E, Bosch J, Yusuf S et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293(11), 1338-1347 (2005). (Pubitemid 40381486)
122. Mosca L, Mochari H, Christian A et al. National study of women's awareness, preventive action, and barriers to cardiovascular health. Circulation 113(4), 525-534 (2006).
123. Witt BJ, Jacobsen SJ, Weston SA et al. Cardiac rehabilitation after myocardial infarction in the community. J. Am. Coll. Cardiol. 44(5), 988-996 (2004). (Pubitemid 39165131)
124. Mosca L, Linfante AH, Benjamin EJ et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 111(4), 499-510 (2005). (Pubitemid 40204436)
125. Stoddard AM, Palombo R, Troped PJ, Sorensen G, Will JC. Cardiovascular disease risk reduction: the Massachusetts WISEWOMAN project. J. Womens Health (Larchmt) 13(5), 539-546 (2004). (Pubitemid 39023319)
126. Viadro CI, Farris RP, Will JC. The WISEWOMAN projects: lessons learned from three states. J. Womens Health (Larchmt) 13(5), 529-538 (2004). (Pubitemid 39023318)
127. Stramba-Badiale M. Women and research on cardiovascular diseases in Europe: a report from the European Heart Health Strategy (EuroHeart) project. Eur. Heart J. 31(14), 1677d-1681d (2010).
128. Melloni C, Berger JS, Wang TY et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ. Cardiovasc. Qual. Outcomes 3(2), 135-142 (2010).
129. Greenland P, Alpert JS, Beller GA et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American college of cardiology foundation/Amercian Heart Association task force on practice guidelines. Circulation 122(25), e584-e636 (2010).